ANXA10

Summary

ANXA10 (annexin A10, HGNC:534) is a protein-coding gene on chromosome 4q32.3, encoding Annexin A10 (Q9UJ72).

This gene encodes a member of the annexin family. Members of this calcium-dependent phospholipid-binding protein family play a role in the regulation of cellular growth and in signal transduction pathways. The function of this gene has not yet been determined.

Source: NCBI Gene 11199 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 53 total
• Druggable target: yes
• MANE Select transcript: NM_007193

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:534
Approved symbol	ANXA10
Name	annexin A10
Location	4q32.3
Locus type	gene with protein product
Status	Approved
Aliases	ANX14
Ensembl gene	ENSG00000109511
Ensembl biotype	protein_coding
OMIM	608008
Entrez	11199

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 retained_intron, 1 protein_coding

ENST00000359299, ENST00000503003, ENST00000507278

RefSeq mRNA: 1 — MANE Select: NM_007193 NM_007193

CCDS: CCDS34096

Canonical transcript exons

ENST00000359299 — 12 exons

Exon	Start	End
ENSE00001015909	168165247	168165326
ENSE00001015910	168128084	168128165
ENSE00001015912	168164198	168164288
ENSE00001015913	168162528	168162641
ENSE00001015915	168139486	168139580
ENSE00001399307	168092537	168092718
ENSE00003483404	168177740	168177793
ENSE00003489525	168187366	168187736
ENSE00003575689	168179217	168179312
ENSE00003598028	168184559	168184681
ENSE00003600309	168181683	168181741
ENSE00003639691	168177890	168177983

Expression profiles

Bgee: expression breadth ubiquitous, 124 present calls, max score 97.92.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.0959 / max 164.4678, expressed in 96 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
50483	0.7021	76
50490	0.1281	8
50484	0.1193	42
50489	0.0608	7
50491	0.0358	10
50485	0.0303	17
50486	0.0195	7

Top tissues by expression

267 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pylorus	UBERON:0001166	97.92	gold quality
right lobe of liver	UBERON:0001114	95.12	gold quality
pancreatic ductal cell	CL:0002079	93.67	gold quality
liver	UBERON:0002107	93.09	gold quality
cardia of stomach	UBERON:0001162	92.52	gold quality
mucosa of stomach	UBERON:0001199	89.16	gold quality
stomach	UBERON:0000945	89.06	gold quality
body of stomach	UBERON:0001161	88.81	gold quality
mucosa of urinary bladder	UBERON:0001259	86.15	silver quality
body of pancreas	UBERON:0001150	85.48	gold quality
epithelial cell of pancreas	CL:0000083	82.22	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.70	gold quality
pancreas	UBERON:0001264	81.09	gold quality
duodenum	UBERON:0002114	79.47	gold quality
fundus of stomach	UBERON:0001160	78.64	gold quality
islet of Langerhans	UBERON:0000006	76.56	gold quality
urinary bladder	UBERON:0001255	75.39	gold quality
gall bladder	UBERON:0002110	74.86	gold quality
ileal mucosa	UBERON:0000331	62.76	silver quality
stromal cell of endometrium	CL:0002255	61.86	gold quality
Brodmann (1909) area 10	UBERON:0013541	60.76	gold quality
right uterine tube	UBERON:0001302	57.73	gold quality
oocyte	CL:0000023	56.89	gold quality
tibialis anterior	UBERON:0001385	56.23	silver quality
lower esophagus	UBERON:0013473	53.72	gold quality
lower esophagus muscularis layer	UBERON:0035833	53.67	gold quality
rectum	UBERON:0001052	52.75	gold quality
buccal mucosa cell	CL:0002336	51.72	gold quality
quadriceps femoris	UBERON:0001377	51.05	gold quality
lower esophagus mucosa	UBERON:0035834	50.71	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-8559	yes	364.21
E-ANND-3	yes	10.46
E-MTAB-7249	yes	6.13

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

29 targeting ANXA10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-219A-5P	99.91	73.36	735
HSA-MIR-4782-3P	99.88	73.31	735
HSA-MIR-6766-3P	99.88	73.38	732
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-2053	99.57	69.15	1635
HSA-MIR-7159-3P	99.51	70.17	1920
HSA-MIR-504-3P	99.30	67.18	1745
HSA-MIR-3675-3P	99.09	67.70	968
HSA-MIR-5197-3P	98.71	67.05	1905
HSA-MIR-508-3P	98.66	69.62	887
HSA-MIR-6731-3P	98.61	67.86	749
HSA-MIR-302F	98.44	69.02	1776
HSA-MIR-218-2-3P	98.08	67.21	601
HSA-MIR-506-5P	98.02	67.41	1065
HSA-MIR-3920	97.75	69.02	1168
HSA-MIR-4445-5P	97.21	66.16	832
HSA-MIR-216B-5P	97.16	66.76	1126
HSA-MIR-8069	97.05	66.79	718
HSA-MIR-4662A-3P	97.02	67.77	941
HSA-MIR-6806-5P	96.37	68.74	587

Literature-anchored findings (GeneRIF, showing 33)

• Reduced expression and homozygous deletion of annexin A10 is associated with gastric carcinoma. (PMID:19582876)
• ANXA10 was aberrantly regulated in gastric carcinoma and suggest that down-regulation of ANXA10 might be involved in gastric carcinogenesis. (PMID:20664964)
• ANXA10 protein expression is a novel marker of gastric differentiation, and is differentially expressed in intestinal and diffuse type gastric carcinoma, with opposite prognostic significance. (PMID:21175800)
• We conclude that ANXA10 may be a clinical relevant marker for predicting outcome in both early and advanced stages of bladder cancer. (PMID:21979422)
• ANXA10 is an indicator of cellular proliferation in OSCCs. Our results suggested that ANXA10 expression might indicate cellular proliferation and ANXA10 might be a potential therapeutic target for the development of new treatments for OSCCs. (PMID:23029062)
• The apoptosis rate in PGC-Fu-ANXA10 group was significantly higher than in PGC-Fu group. (PMID:23073794)
• Overexpression of annexin A10 increases their sensitivity to apoptosis and reduces colony formation. (PMID:23715859)
• Our study results indicate that the inclusion of ANXA10 in an immunohistochemical panel will be helpful in the differential diagnosis of adenocarcinoma of an unknown primary site. (PMID:24024557)
• immunohistochemistry for annexin A10 may be a useful marker to distinguish sporadic from Lynch syndrome-associated microsatellite-unstable colon cancer (PMID:24625416)
• ANXA10+ MSI-H colon carcinomas are characterized by serrated pathway features, including proximal location, female predominance, and high frequencies of CIMP-H status and MLH1 methylation. (PMID:24909058)
• Our results indicated that ANXA10 expression is implicated in gastric programming in serrated-pathway-associated colorectal carcinoma. (PMID:25081749)
• there is a correlation between high ANXA10 expression and serrated growth pattern in colorectal carcinoma (PMID:25395067)
• Annexin A10 expression is associated with poor clinical behavior and can be used a supportive surrogate marker of the serrated neoplasia pathway in invasive colorectal carcinomas. (PMID:26361422)
• Results show that ANXA1 and ANXA10 are highly expressed in pancreatic ductal adenocarcinoma and its metastases to the liver comparing to intrahepatic cholangiocellular carcinoma. (PMID:26644413)
• expression of ANXA10 was significantly correlated with the progression of pancreatic precursor lesions towards pancreatic adenocarcinoma (PMID:28369074)
• Annexin A10 and HES-1 Immunohistochemistry in Right-sided Traditional Serrated Adenomas Suggests an Origin From Sessile Serrated Adenoma. (PMID:30653033)
• that ANXA10 induced by the interaction with tumor-associated macrophages in the tumor microenvironment is associated with cell growth and poor prognosis in human esophageal squamous cell carcinomas tissues (PMID:30758105)
• ANXA10 was expressed by cells in the ovarian cancer cell lines. Patients with low expression and high expression of ANXA10 were 61.86% (73/118) and 38.14% (45/118), respectively. (PMID:31363077)
• ANXA10 was an independent prognostic biomarker of PHCCA and DCCA but not IHCCA. ANXA10 promoted the progression of PHCCA and facilitated metastasis by promoting the EMT process via the PLA2G4A/PGE2/STAT3 pathway. (PMID:31492557)
• Annexin A10 is involved in the induction of pancreatic duodenal homeobox1 in gastric cancer tissue, cells and organoids. (PMID:31789399)
• Annexin A10 Expression Is Associated With Poor Prognosis in Small Bowel Adenocarcinoma. (PMID:33788726)
• Knockdown of ANXA10 inhibits proliferation and promotes apoptosis of papillary thyroid carcinoma cells by down-regulating TSG101 thereby inactivating the MAPK/ERK signaling pathway. (PMID:34032966)
• ANXA10 promotes melanoma metastasis by suppressing E3 ligase TRIM41-directed PKD1 degradation. (PMID:34324862)
• The prognostic significance of annexin A family in glioblastoma. (PMID:34398393)
• High Annexin A10 expression is correlated with poor prognosis in pancreatic ductal adenocarcinoma. (PMID:34821375)
• Annexin A10 Expression as a Novel Prognostic Marker in Lung Adenocarcinoma. (PMID:35220218)
• Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma. (PMID:35227227)
• Transcriptomic Analysis of Annexin A10 and Chemosensitivity in Gastric Adenocarcinoma Cells. (PMID:35346989)
• ANXA10 Expression Is Inversely Associated with Tumor Stage, Grade, and TP53 Expression in Upper and Lower Urothelial Carcinoma. (PMID:35780773)
• GATA6 regulates expression of annexin A10 (ANXA10) associated with epithelial-mesenchymal transition of oral squamous cell carcinoma. (PMID:36265396)
• SOX2-Induced Linc-ROR Upregulation Inhibits Gastric Carcinoma Cell Proliferation and Metastasis Via the miR-580-3p/ANXA10 Pathway. (PMID:36451051)
• ANXA10 is a prognostic biomarker and suppressor of hepatocellular carcinoma: a bioinformatics analysis and experimental validation. (PMID:36709331)
• Strong Annexin A10 Expression Supports a Pancreatic Primary and Combined Annexin A10, Claudin 18, and SOX2 Expression Supports an Esophagogastric Origin in Carcinomas of Unknown Primary. (PMID:36730833)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	anxa14	ENSDARG00000100104
mus_musculus	Anxa10	ENSMUSG00000031635
rattus_norvegicus	Anxa10	ENSRNOG00000014339
drosophila_melanogaster	AnxB9	FBGN0000083
drosophila_melanogaster	AnxB11	FBGN0030749

Paralogs (12): ANXA13 (ENSG00000104537), ANXA11 (ENSG00000122359), ANXA1 (ENSG00000135046), ANXA7 (ENSG00000138279), ANXA3 (ENSG00000138772), ANXA9 (ENSG00000143412), ANXA5 (ENSG00000164111), ANXA2 (ENSG00000182718), ANXA4 (ENSG00000196975), ANXA6 (ENSG00000197043), ANXA8L1 (ENSG00000264230), ANXA8 (ENSG00000265190)

Protein

Protein identifiers

Annexin A10 — Q9UJ72 (reviewed: Q9UJ72)

Alternative names: Annexin-10, Annexin-14

All UniProt accessions (1): Q9UJ72

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the annexin family.

RefSeq proteins (1): NP_009124* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001464	Annexin	Family
IPR008156	ANX10	Family
IPR018252	Annexin_repeat_CS	Conserved_site
IPR018502	Annexin_repeat	Repeat
IPR037104	Annexin_sf	Homologous_superfamily

Pfam: PF00191

UniProt features (9 total): repeat 4, sequence conflict 3, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UJ72-F1	95.38	0.94

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 117 (showing top): chr4q32, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, MORF_RAD51L3, BRUECKNER_TARGETS_OF_MIRLET7A3_DN, NKX61_01, SENESE_HDAC1_AND_HDAC2_TARGETS_DN, CAIRO_HEPATOBLASTOMA_CLASSES_DN, MORF_CTSB, MORF_IL4, RIGGI_EWING_SARCOMA_PROGENITOR_DN, CAIRO_HEPATOBLASTOMA_DN, MORF_ATF2, TGGAAA_NFAT_Q4_01, TAATTA_CHX10_01, MORF_PAX7

GO Biological Process (0):

GO Molecular Function (4): phosphatidylserine binding (GO:0001786), calcium ion binding (GO:0005509), calcium-dependent phospholipid binding (GO:0005544), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), cytoplasm (GO:0005737), plasma membrane (GO:0005886), vesicle membrane (GO:0012506)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
phospholipid binding	2
anion binding	1
modified amino acid binding	1
metal ion binding	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1
membrane	1
cell periphery	1
organelle membrane	1
vesicle	1

Protein interactions and networks

STRING

736 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ANXA10	UPK1B	O75841	620
ANXA10	CCDC14	Q49A88	536
ANXA10	CTSE	P14091	506
ANXA10	TFF2	Q03403	490
ANXA10	VSIG1	Q86XK7	479
ANXA10	GEN1	Q17RS7	415
ANXA10	MUC6	Q6W4X9	412
ANXA10	TRAM2	Q15035	401
ANXA10	CRH	P06850	399
ANXA10	LRRC32	Q14392	387
ANXA10	MUC5AC	P98088	386
ANXA10	THTPA	Q9BU02	375
ANXA10	IKZF2	Q9UKS7	357
ANXA10	IGF2	P01344	354
ANXA10	SPOCK3	Q9BQ16	353

IntAct

17 interactions, top by confidence:

A	B	Type	Score
EDC3	ANXA10	psi-mi:“MI:0915”(physical association)	0.870
ANXA10	EDC3	psi-mi:“MI:0915”(physical association)	0.870
BLVRB	ANXA10	psi-mi:“MI:0915”(physical association)	0.560
EDC3	ANXA10	psi-mi:“MI:0915”(physical association)	0.000
BLVRB	ANXA10	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (19): EDC3 (Two-hybrid), EDC3 (Two-hybrid), ANXA10 (Affinity Capture-MS), ANXA10 (Affinity Capture-MS), CUL4A (Affinity Capture-Western), ANXA10 (Affinity Capture-Western), ANXA10 (Two-hybrid), ANXA10 (Two-hybrid), EDC3 (Two-hybrid), ANXA10 (Affinity Capture-MS), CUL4A (Affinity Capture-Western), ANXA10 (Affinity Capture-Western), PKD1 (Affinity Capture-Western), ANXA10 (Affinity Capture-Western), TSG101 (Affinity Capture-Western)

ESM2 similar proteins: A0A4X1T4U3, A2SW69, A5A6L7, A6H603, A6NMY6, C1L7Y4, O35640, O76027, O97529, P04272, P07355, P07356, P13928, P14950, P17785, P19620, P21671, P24551, P24801, P27006, P51074, P51901, P58107, P93157, Q07936, Q2Q1M6, Q3ZBE0, Q3ZC08, Q5R5A0, Q5VT79, Q66KB7, Q6NVG1, Q6TEQ7, Q86U10, Q86VI3, Q8MIR4, Q8R0W0, Q8SPR7, Q92040, Q92108

Diamond homologs: A2SW69, A5A6L7, A5A6M2, A6NMY6, C0HJG9, C1L7Y4, C4QH88, O35639, O35640, O76027, O97529, P04083, P04272, P07150, P07355, P07356, P08132, P08133, P08758, P09525, P10107, P12429, P13214, P13928, P14087, P14668, P14669, P14824, P14950, P17153, P17785, P19619, P19620, P20072, P20073, P22464, P22465, P24551, P24639, P24801

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

53 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	39
Likely benign	3
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1694 predictions. Top by Δscore:

Variant	Effect	Δscore
4:168128163:TTGG:T	donor_loss	1.0000
4:168128164:TGGT:T	donor_loss	1.0000
4:168128165:GGT:G	donor_loss	1.0000
4:168128166:G:GG	donor_gain	1.0000
4:168128166:GTA:G	donor_loss	1.0000
4:168128167:T:A	donor_loss	1.0000
4:168139481:TCCA:T	acceptor_loss	1.0000
4:168139483:CAG:C	acceptor_loss	1.0000
4:168139484:A:AG	acceptor_gain	1.0000
4:168139484:AGACT:A	acceptor_gain	1.0000
4:168139485:G:GC	acceptor_gain	1.0000
4:168139485:GA:G	acceptor_gain	1.0000
4:168139485:GAC:G	acceptor_gain	1.0000
4:168139485:GACT:G	acceptor_gain	1.0000
4:168139485:GACTG:G	acceptor_gain	1.0000
4:168139576:GCCGG:G	donor_gain	1.0000
4:168139579:GG:G	donor_gain	1.0000
4:168139580:GG:G	donor_gain	1.0000
4:168139581:G:A	donor_loss	1.0000
4:168139581:G:GG	donor_gain	1.0000
4:168162522:CCACA:C	acceptor_loss	1.0000
4:168162523:CACAG:C	acceptor_loss	1.0000
4:168162525:CAG:C	acceptor_loss	1.0000
4:168162526:A:AG	acceptor_gain	1.0000
4:168162526:A:C	acceptor_loss	1.0000
4:168162526:AG:A	acceptor_gain	1.0000
4:168162527:G:GC	acceptor_gain	1.0000
4:168162527:GG:G	acceptor_gain	1.0000
4:168162640:AGGT:A	donor_loss	1.0000
4:168162641:GGTAG:G	donor_loss	1.0000

AlphaMissense

2166 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:168139541:G:C	R52S	0.989
4:168139541:G:T	R52S	0.989
4:168162625:T:C	L98P	0.987
4:168177788:G:C	A177P	0.985
4:168184629:T:A	I285K	0.984
4:168165310:T:C	L155P	0.982
4:168184590:G:T	R272M	0.981
4:168184620:T:C	L282P	0.981
4:168162615:G:C	A95P	0.979
4:168184605:G:T	R277I	0.979
4:168179228:T:C	F214L	0.978
4:168179230:T:A	F214L	0.978
4:168179230:T:G	F214L	0.978
4:168139540:G:C	R52T	0.977
4:168177975:T:C	L207P	0.977
4:168184607:A:C	S278R	0.977
4:168184609:T:A	S278R	0.977
4:168184609:T:G	S278R	0.977
4:168162633:G:C	A101P	0.976
4:168181725:T:C	L256S	0.976
4:168184605:G:C	R277T	0.976
4:168184611:A:T	E279V	0.976
4:168164244:G:T	R119I	0.975
4:168184629:T:G	I285R	0.975
4:168165310:T:A	L155H	0.974
4:168184606:A:C	R277S	0.974
4:168184606:A:T	R277S	0.974
4:168128114:T:C	F17L	0.973
4:168128116:C:A	F17L	0.973
4:168128116:C:G	F17L	0.973

dbSNP variants (sampled 300 via entrez): RS1000065624 (4:168165067 T>A), RS1000071207 (4:168120167 A>C), RS1000073257 (4:168133741 A>G), RS1000106275 (4:168153732 T>C), RS1000107020 (4:168116617 A>G), RS1000120548 (4:168109425 A>C), RS1000137081 (4:168163521 C>T), RS1000207753 (4:168167599 A>G), RS10002305 (4:168127955 T>A,C), RS1000276086 (4:168113646 C>T), RS10002781 (4:168107356 C>A,G,T), RS1000290010 (4:168181304 T>A,C), RS1000294678 (4:168116016 A>T), RS1000321234 (4:168144954 T>G), RS1000388070 (4:168129353 T>A)

Disease associations

OMIM: gene MIM:608008 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST002701_25	Verbal declarative memory	3.000000e-08
GCST005024_96	Pursuit maintenance gain	4.000000e-06
GCST008367_10	Plasma anti-thyroglobulin and anti-thyroid peroxidase levels (bivariate analysis)	4.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004874	memory performance
EFO:0006805	word list delayed recall measurement
EFO:0008433	pursuit maintenance gain measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6196184 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

66 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Aflatoxin B1	affects expression, decreases expression, decreases methylation	3
bisphenol A	affects cotreatment, decreases expression, affects methylation	2
sodium arsenite	decreases expression, increases expression	2
perfluorooctane sulfonic acid	decreases expression, increases expression	2
(+)-JQ1 compound	decreases expression, increases expression	2
Acetaminophen	decreases expression	2
Benzo(a)pyrene	decreases expression	2
Tetrachlorodibenzodioxin	decreases reaction, increases expression, decreases expression	2
Thiram	increases expression	2
Tobacco Smoke Pollution	increases expression	2
Zinc	affects cotreatment, affects expression, increases expression	2
Cadmium Chloride	increases expression	2
fluxapyroxad	increases expression	1
bisphenol F	affects cotreatment, decreases expression	1
ethoprop	increases expression	1
methyleugenol	decreases expression	1
propionaldehyde	increases expression	1
pirinixic acid	increases activity, affects binding, decreases expression	1
carbendazim	increases expression	1
lead acetate	increases expression	1
enilconazole	increases expression	1
butyraldehyde	increases expression	1
tobacco tar	decreases expression	1
cupric chloride	increases expression	1
perfluoropropionic acid	increases expression	1
iprodione	increases expression	1
prochloraz	increases expression	1
propiconazole	increases expression	1
pentanal	increases expression	1
flusilazole	increases expression	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL6106835	Binding	Induction of ANXA10 degradation in human MDA-MB-231 cells at 0.5 to 6 uM incubated for 24 hrs by Western blot analysis relative to control	Discovery of a Novel 1,4-Benzodiazepine Derivative as a Highly Selective ANXA3 Degrader for the Treatment of Triple-Negative Breast Cancer. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.